Systematic Review of Economic Evaluation of Targeted Drugs for Colorectal Cancer Treatment in China

OBJECTIVE To inform the progress in studies on economic evaluation of targeted drugs for colorectal cancer treatment in China, and to summarize their model structure, parameter inclusion and research results. METHODS PubMed, Web of Science, Embase, Scopus, CNKI, VIP, Wanfang Data databases were searched from inception to July 31, 2022 to collect studies about the economic evaluation of targeted drugs for colorectal cancer. The information of literature was extracted using Excel, and the quality of the literatures was assessed using the CHEERS 2022. RESULTS A total of 871 literatures were obtained, and finally 17 were included. The quality of literatures were good, involving 5 targeted drugs, all of which were cost-utility analysis. Only one study used prospective cohort study and rest used modelling study. Compared with standard chemotherapy, cetuximab, bevacizumab, and panitumumab were not cost-effective. Anti-epidermal growth factor receptor monoclonal antibody(Anti-EGFR mAb) was more cost-effective than bevacizumab as a first-line treatment for patients with RAS wild-type left-sided metastatic colorectal cancer. Fruquintinib had economic advantages over regorafenib. CONCLUSION It is suggested to comprehensively compare the economy of multiple various targeted therapeutic regimens and focus on more targeted therapy options in the future, with attention to the impact of biomarkers and primary tumor location. National medical insurance reimbursement, preferential policies of enterprises and domestic new drug research and development can bring the benefit of drugs to patients.